Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Total Valuation
Caris Life Sciences, Inc. has a market cap or net worth of $5.13B. The enterprise value is $4.71B.
Market Cap$5.13B
Enterprise Value$4.71B
Share Statistics
Caris Life Sciences, Inc. has 282,579,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,579,930
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Caris Life Sciences, Inc.’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is 4.52%.
Return on Equity (ROE)-0.93
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)4.52%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee459.04K
Profits Per Employee-38.49K
Employee Count1,769
Asset Turnover0.72
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Caris Life Sciences, Inc. is ―. Caris Life Sciences, Inc.’s PEG ratio is 2.83.
PE Ratio―
PS Ratio55.55
PB Ratio78.14
Price to Fair Value78.14
Price to FCF674.37
Price to Operating Cash Flow585.67
PEG Ratio2.83
Income Statement
In the last 12 months, Caris Life Sciences, Inc. had revenue of 812.03M and earned -537.96M in profits. Earnings per share was -1.90.
Revenue812.03M
Gross Profit539.17M
Operating Income45.11M
Pretax Income-68.09M
Net Income-537.96M
EBITDA11.38M
Earnings Per Share (EPS)-1.90
Cash Flow
In the last 12 months, operating cash flow was 51.82M and capital expenditures -18.95M, giving a free cash flow of 32.87M billion.
Operating Cash Flow51.82M
Free Cash Flow32.87M
Free Cash Flow per Share0.12
Dividends & Yields
Caris Life Sciences, Inc. pays an annual dividend of $0.3, resulting in a dividend yield of ―
Dividend Per Share$0.3
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.97
52-Week Price Change-33.39%
50-Day Moving Average31.76
200-Day Moving Average―
Relative Strength Index (RSI)34.86
Average Volume (3m)2.31M
Important Dates
Caris Life Sciences, Inc. upcoming earnings date is Aug 18, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Caris Life Sciences, Inc. as a current ratio of 7.85, with Debt / Equity ratio of 65.65%
Current Ratio7.85
Quick Ratio7.85
Debt to Market Cap<0.01
Net Debt to EBITDA-36.80
Interest Coverage Ratio0.79
Taxes
In the past 12 months, Caris Life Sciences, Inc. has paid 469.87M in taxes.
Income Tax469.87M
Effective Tax Rate-6.90
Enterprise Valuation
Caris Life Sciences, Inc. EV to EBITDA ratio is 3.93K, with an EV/FCF ratio of 668.11.
EV to Sales55.04
EV to EBITDA3.93K
EV to Free Cash Flow668.11
EV to Operating Cash Flow537.47
Balance Sheet
Caris Life Sciences, Inc. has $800.09M in cash and marketable securities with $378.99M in debt, giving a net cash position of $421.10M billion.
Cash & Marketable Securities$800.09M
Total Debt$378.99M
Net Cash$421.10M
Net Cash Per Share$1.49
Tangible Book Value Per Share$0.33
Margins
Gross margin is 66.40%, with operating margin of 5.56%, and net profit margin of -66.25%.
Gross Margin66.40%
Operating Margin5.56%
Pretax Margin-8.38%
Net Profit Margin-66.25%
EBITDA Margin1.40%
EBIT Margin-1.38%
Analyst Forecast
The average price target for Caris Life Sciences, Inc. is $39.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.78
Price Target Upside119.17% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―